This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

JAN VOLAVKA, MD, PHD
The Nathan S. Kline Institute for Psychiatric Research Orangeburg, NY 10962

RICHARD DOUYON, MD; ANTONIO CONVIT, MD; PAL CZOBOR, PHD; THOMAS B. COOPER, MA
Orangeburg, NY

Arch Gen Psychiatry. 1992;49(12):999-1000.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Davidson et al¹ reported that plasma homovanillic acid (pHVA) concentrations decreased in a group of neuroleptic responders (n=7) but were unchanged in nonresponders (n=13). Within the framework of a large experiment,² we collected analogous data. To replicate their results, we emulated their analyses with our data set.

Our experiment² used 176 acutely exacerbated schizophrenic or schizoaffective patients. After a placebo period, they were randomly assigned to one of three plasma levels of haloperidol for 6 weeks. Weekly measures included haloperidol plasma levels, the Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), and, in a subset of patients, pHVA (assayed with a modification of a published method³ using gas chromatography/mass spectroscopy and deuterated HVA as an internal standard).

Emulating the sampling criteria of Davidson et al,¹ we selected 28 schizophrenic patients who had a minimum of four points on the CGI at baseline . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?